LivingGLP1
Study S001115

Effect of Tirzepatide on Functional Outcomes in Patients With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy: A Multicenter, Randomized, Controlled, Blinded Outcome Assessment Trial

ClinicalTrials.gov recordStatistical Analysis Plan (PDF)

Registration

Registration
NCT07734792
Acronym
TOPAZ
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2; PHASE3
Masking
SINGLE
Status
NOT_YET_RECRUITING
Enrollment
726
Start
2026-09-20
Primary completion
2028-05-31
Lead sponsor
yifang zhu
Conditions
Acute Ischemic Stroke (AIS)
Interventions
DRUG:Tirzepatide; OTHER:Standard Medical Care (SMC)
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome [90 ± 7 days after randomization]
  • The primary safety outcome: All-cause mortality [90 ± 7 days]

Linked records (11)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0002511Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.
Wang H, Nature communications
2025Randomized trialPMID 41392086DOIregistry reference RESULT:41392086
R0009707Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
Krüger N, JAMA
2025Nonrandomized studyPMID 40886075DOIregistry reference RESULT:40886075
R0017665Tirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, The New England journal of medicine
2025Randomized trialPMID 39536238DOIregistry reference RESULT:39536238
R0020489Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways.
Wang D, Molecular medicine (Cambridge, Mass.)
2025PreclinicalPMID 40702450DOIregistry reference RESULT:40702450
R0008068Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, The New England journal of medicine
2023Randomized trialPMID 37952131DOIregistry reference RESULT:37952131
R0005732Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists.
Goldenberg RM, Stroke
2022Narrative reviewPMID 35259929DOIregistry reference RESULT:35259929
R0014572Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
Kopp KO, Pharmacological research
2022Narrative reviewPMID 36372278DOIregistry reference RESULT:36372278
R0021917A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
Furihata K, Diabetes, obesity & metabolism
2022Randomized trialPMID 34647404DOIregistry reference RESULT:34647404
R0013656Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, The New England journal of medicine
2021Randomized trialPMID 34170647DOIregistry reference RESULT:34170647
R0017797Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
Hölscher C, Neuropharmacology
2018Narrative reviewPMID 29402504DOIregistry reference RESULT:29402504
R0012898The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice.
Li PC, BMC neuroscience
2016PreclinicalPMID 27296974DOIregistry reference RESULT:27296974